Our mission is to create value through product development by leveraging expertise and partnerships.In-license early stage products (first-in-class/best-in-class) with large unmet market opportunities, add value through R&D, preclinical and early clinical development, then outlicense or sell to major pharmaceutical companies. Collaborate with biopharmaceutical companies by assisting them in developing their business by product development in the US, in-licensing and out-licensing.
Apatinib Mesylate is a small molecule drug candidate which has been approved in China and has completed Phase 1/2A development in the US. It is being developed for the treatment of certain solid tumor cancers including Metastatic Gastric Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Metastatic Breast Cancer, and Non-Small Cell Lung Cancer. It was first synthesized and patented by Advenchen Laboratories in Southern California and is being developed in numerous clinical trials throughout the world.
LSK-1401 is a tyrosine kinase inhibitor that targets inhibition of the Bruton’s tyrosine kinase(BTK), which is kinase that plays a crucial role in B-cell malignancies and rheumatoid arthritis. It is an orally-administered, selective and irreversible inhibitor of the enzyme Bruton’s tyrosine kinase. Specifically it is designed to maintain activity in mutated BTK. It is being developed in numerous clinical trials throughout the world.